{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.02","value":"29.9"},{"groupId":"OG001","spread":"16.98","value":"15.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"176"}],"units":"Participants"}],"description":"The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.","dispersionType":"Standard Deviation","groups":[{"description":"CC-5013 (lenalidomide) plus oral high-dose dexamethasone","id":"OG000","title":"CC-5013/Dex"},{"description":"Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone","id":"OG001","title":"Placebo/Dex"}],"paramType":"MEAN","populationDescription":"Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.","reportingStatus":"POSTED","timeFrame":"30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)","title":"Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)","type":"SECONDARY","unitOfMeasure":"Weeks"}